Mendus AB CEO Erik Manting talks about the latest data presented at #EHA2024 demonstrating the link between functional immune responses and long-term survival in AML patients treated with Mendus lead product #vididencel Watch the interview here https://lnkd.in/eYCchRwS #ChangingTheCourseOfCancerTreatment
Mendus AB
Forskning inom bioteknik
Stockholm, Stockholm County 3 793 följare
Changing the course of cancer treatment
Om oss
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
- Webbplats
-
https://mendus.com/
Extern länk för Mendus AB
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Stockholm, Stockholm County
- Typ
- Publikt aktiebolag
Adresser
-
Primär
Få vägbeskrivning
Västra Trädgårdsgatan 15
Stockholm, Stockholm County 11153, SE
-
Få vägbeskrivning
Emmy Noetherweg 2K
Plus Ultra Leiden
Leiden, South Holland 2333 BK, NL
Anställda på Mendus AB
Uppdateringar
-
We are excited to announce that clinical data from the ALISON clinical trial with Mendus AB lead product #vididencel in #ovariancancer were presented at #ESMOGynae24. For more details, please visit #ChangingTheCourseOfCancerTreatment
-
-
Mendus AB presented data at the annual #EHA2024 congress demonstrating the potential of its lead product #vididencel to stimulate functional immune responses associated with long-term survival in #AcuteMyeloidLeukemia. Please visit https://lnkd.in/evtJ-ZBn for more details. #ChangingTheCourseOfCancerTreatment
-
-
Mendus AB CEO Erik Manting talks about the company’s lead product #vididencel and additional pipeline programs in an interview with Edison’s Soo Romanoff
Mendus AB is a clinical-stage immuno-oncology company focused on the development of off-the-shelf therapies for haematological and solid tumours. Edison’s Soo Romanoff recently caught up with company’s CEO Erik Manting. Watch the full interview here: https://lnkd.in/ea9Fmv9j #IMMU #OMX
-
The Mendus AB team is looking forward to participate in several industry events in June. For more information on the events, please visit > https://lnkd.in/ewBSP3Sw #ChangingTheCourseOfCancerTreatment #BIO2024 #EHA2024 #ESMOGynae24
-
Watch the replay of the InFocus interview with Mendus AB CEO Erik Manting at #RedeyeGrowthDay2024 via https://lnkd.in/eXuwq5YA #ChangingTheCourseOfCancerTreatment
-
-
Mendus AB CEO Erik Manting will present at the #RedeyeGrowthDay2024 and participate in an in-depth interview & Q&A today at 15.40 CEST. Watch the live broadcast via https://lnkd.in/dKDM-VfH #ChangingTheCourseOfCancerTreatment
-
-
Mendus AB CMO Jeroen Rovers is attending the ALLG Scientific Meeting in Adelaide. We are excited to be part of ALLG’s excellent medical scientific network and to collaborate in the execution of the AMLM22-CADENCE trial for AML patients in need of maintenance therapy. #ChangingTheCourseOfCancerTreatment
At the ALLG National Scientific Meeting tomorrow we look forward to the launch of our latest cutting edge trial with Mendus. The AMLM22 CADENCE trial is opening at 9 Australian hospitals in June. Led by Prof Andrew Wei and Dr Vicky Ling, the CADENCE trial will offer patients a unique opportunity to access Vididencel an intradermally administered dendritic cell vaccine. Pictured below: Jeroen Rovers (Mendus) with ALLG team members Naomi Sprigg, Shivani Arora & Joanna Nkyekyer. #ALLGMay2024 #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology #haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness
-
-
Please see the interview by Inderes analyst Antti Siltanen with Mendus AB CEO Erik Manting following publication of the 2024 Q1 financial report. https://lnkd.in/eC4Acvzb #ChangingTheCourseOfCancerTreatment
Mendus Q1’24: Progress with main partnerships
https://www.youtube.com/
-
Mendus AB publishes financial report for 1st quarter of 2024 and will host a quarterly update call today, May 17 at 14:00 CEST. For more details, see https://lnkd.in/e96FVx-D #ChangingTheCourseOfCancerTreatment